2019 | 第 3 页，共 20 页 | Certara

Quantitative Systems Toxicology Approach Integrates Simcyp PBPK and Core Hepatocyte Metabolism: a Case Study with Valproic Acid

2019 年 10 月 16 日

Certara 庆祝 Simcyp Simulator 协会成立 20 周年

2019 年 10 月 16 日

Oct 16, 2019 The most influential scientific research consortium of its kind: 37 biopharmaceutical companies work in a pre-competitive environment to advance PBPK modeling and simulation, progress new drug and biologics research, create new regulatory frontiers, foster ongoing modeling and simulation education, and present industry awards

Prediction of mAb disposition in hepatic impairment – Evolocumab as a case study

2019 年 10 月 15 日

Use of a physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model to guide dose adjustments to S-warfarin in different populations

2019 年 10 月 15 日

Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed PBPK Model of Ritonavir Norvir® Tablet Absorption in Humans Under Fasted and Fed State Conditions

2019 年 10 月 15 日

Accounting for CYP2C19 mechanism based inhibition and CYP1A2 induction in a PBPK model for omeprazole

2019 年 10 月 11 日

Physiological verification of a geriatric population using the Simcyp R package

2019 年 10 月 11 日

Estimation of Effective pKa of Bicarbonate Buffer

2019 年 10 月 11 日

Quantification of Human Blood-Brain Barrier Transporters in Health and in Dementia by Global and Targeted Proteomics

2019 年 10 月 11 日

The Molecular Stethoscope: RNA of Drug Metabolising Enzymes in Circulating Vesicles Correlates with their Specific Protein Content in the Liver

2019 年 10 月 11 日

第 3 页，共 20 页

沪ICP备2022021526号

Powered by Translations.com GlobalLink OneLink Software